Invesco Ltd. Ascendis Pharma A/S Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Invesco Ltd. holds 917,903 shares of ASND stock, worth $188 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

917,903

Previous 947,226 3.1%

Holding current value

$188 Million

Previous $163 Million 11.62%

% of portfolio

0.03%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$163.32 - $205.91 $4.79 Million - $6.04 Million	-29,323 Reduced 3.1%	917,903 $182 Million
Q2 2025 Aug 13, 2025	SELL	$137.41 - $179.1 $34.5 Million - $45 Million	-251,252 Reduced 20.96%	947,226 $163 Million
Q1 2025 May 12, 2025	BUY	$119.49 - $168.84 $5.07 Million - $7.17 Million	42,465 Added 3.67%	1,198,478 $187 Million
Q4 2024 Feb 13, 2025	SELL	$122.0 - $146.6 $760,304 - $913,611	-6,232 Reduced 0.54%	1,156,013 $159 Million
Q3 2024 Nov 12, 2024	BUY	$113.0 - $153.43 $6.3 Million - $8.56 Million	55,796 Added 5.04%	1,162,245 $174 Million

Q2 2024 Aug 13, 2024	BUY	$121.07 - $153.67 $17.2 Million - $21.8 Million	141,786 Added 14.7%	1,106,449 $151 Million
Q1 2024 May 14, 2024	BUY	$123.45 - $159.4 $7.01 Million - $9.05 Million	56,752 Added 6.25%	964,663 $146 Million
Q4 2023 Feb 12, 2024	BUY	$86.1 - $127.36 $20.3 Million - $30 Million	235,785 Added 35.08%	907,911 $114 Million
Q3 2023 Nov 13, 2023	BUY	$86.5 - $103.97 $4.97 Million - $5.97 Million	57,413 Added 9.34%	672,126 $62.9 Million
Q2 2023 Aug 11, 2023	SELL	$69.96 - $97.84 $2.23 Million - $3.12 Million	-31,847 Reduced 4.93%	614,713 $54.9 Million
Q1 2023 May 12, 2023	SELL	$104.9 - $126.78 $1.49 Million - $1.8 Million	-14,226 Reduced 2.15%	646,560 $69.3 Million
Q4 2022 Feb 13, 2023	BUY	$99.42 - $131.97 $6.04 Million - $8.02 Million	60,763 Added 10.13%	660,786 $80.7 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $619,133 - $812,174	7,368 Added 1.24%	600,023 $62 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $33.1 Million - $49.9 Million	-424,435 Reduced 41.73%	592,655 $55.1 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $1.44 Million - $1.91 Million	14,047 Added 1.4%	1,017,090 $119 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $3.08 Million - $4.11 Million	-24,219 Reduced 2.36%	1,003,043 $135 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $14.8 Million - $23.3 Million	-131,762 Reduced 11.37%	1,027,262 $164 Million
Q2 2021 Aug 17, 2021	BUY	$121.62 - $145.29 $51.7 Million - $61.7 Million	424,732 Added 57.84%	1,159,024 $152 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $4.05 Million - $5.62 Million	-32,412 Reduced 4.23%	734,292 $94.6 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $141,372 - $170,880	-935 Reduced 0.12%	766,704 $128 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $22.1 Million - $25.4 Million	164,834 Added 27.34%	767,639 $118 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $929,534 - $1.31 Million	8,384 Added 1.41%	602,805 $89.2 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $106,516 - $159,330	1,098 Added 0.19%	594,421 $66.9 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $38.9 Million - $59.2 Million	-425,269 Reduced 41.75%	593,323 $82.5 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $406,766 - $504,849	4,246 Added 0.42%	1,018,592 $98.1 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $99 Million - $122 Million	924,169 Added 1024.84%	1,014,346 $117 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $3.35 Million - $7.01 Million	-53,962 Reduced 37.44%	90,177 $10.6 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $7.95 Million - $10 Million	144,139 New	144,139 $9.03 Million

Others Institutions Holding ASND

# of Institutions

318

Shares Held

65M

Call Options Held

476K

Put Options Held

142K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.4B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account